Protocols
2 protocol(s) meet the specified criteria
Drug: TALIMOGENE LAHERPAREPVEC
Protocol No.TitleStatus
LCCC1626Phase Ib/II Study Of IV Nivolumab And Intrapleural Talmogene Laherparepvec For Patients With Malignant Pleural Effusion Open
NCI-10057-CIRBA Phase II Study of Talimogene Iaherparepvec Followed by Talimogene Iaherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin TumorsOpen